Three-year clinical outcome after chondrocyte transplantation using a hyaluronan matrix for cartilage repair

• Published in: European journal of radiology 2006, Vol.57 (1), p.3-8
• Main Authors: Nehrer, S., Domayer, S., Dorotka, R., Schatz, K., Bindreiter, U., Kotz, R.
• Format: Article
• Language: English
• Subjects: Adult; Autologous chondrocyte transplantation; Biocompatible Materials; Cartilage defects; Cartilage, Articular - injuries; Cartilage, Articular - surgery; Chondrocytes - transplantation; Clinical outcome; Female; Humans; Hyaluronan matrix; Hyaluronic Acid - therapeutic use; Knee Injuries - rehabilitation; Knee Injuries - surgery; Male; Prospective Studies; Prostheses and Implants; Recovery of Function; Tissue Engineering; Transplantation, Autologous; Treatment Outcome
• ISSN: 0720-048X; 1872-7727
• DOI: 10.1016/j.ejrad.2005.08.005

Repair of articular cartilage represents a significant clinical problem and although various new techniques – including the use of autologous chondrocytes – have been developed within the last century the clinical efficacy of these procedures is still discussed controversially. Although autologous chondrocyte transplantation (ACT) has been widely used with success, it has several inherent limitations, including its invasive nature and problems related to the use of the periosteal flap. To overcome these problems autologous chondrocytes transplantation combined with the use of biodegradable scaffolds has received wide attention. Among these, a hyaluronan-based scaffold has been found useful for inducing hyaline cartilage regeneration. In the present study, we have investigated the mid-term efficacy and safety of Hyalograft ® C grafts in a group of 36 patients undergoing surgery for chronic cartilage lesions of the knee. Clinical Outcome was assessed prospectively before and at 12, 24, and 36 months after surgery. No major adverse events have been reported during the 3-year follow-up. Significant improvements of the evaluated scores were observed ( P < 0.02) at 1 year and a continued increase of clinical performance was evident at 2 and 3 years follow-up. Patients under 30 years of age with single lesions showed statistically significant improvements at all follow-up visits compared to those over 30 with multiple defects ( P < 0.01). Hyalograft ® C compares favorably with classic ACT and is particularly indicated in younger patients with single lesions. The graft can be implanted through a miniarthrotomy and needs no additional fixation with sutures except optional fibrin gluing at the defect borders. These results suggest that Hyalograft ® C is a valid alternative to ACT.